|
US2007184078A1
|
|
Packaging system
|
|
AU2005202965A1
|
|
Method of treating amyloid beta precursor disorders
|
|
WO2006002031A1
|
|
Sustained release dosage forms
|
|
WO2006002032A1
|
|
Sustained release neutralized divalproex sodium
|
|
US2005276850A1
|
|
Controlled release sodium valproate formulation
|
|
AU2004201520A1
|
|
HMG-COA reductase inhibitor extended release formulations
|
|
AU2003245504A1
|
|
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
|
AU2003241537A8
|
|
Biguanide formulations
|
|
WO02074285A1
|
|
Controlled release sulfonylurea formulation
|
|
EP1366061A2
|
|
Method of treating amyloid beta precursor disorders
|
|
US6683112B2
|
|
Gabapentin prodrugs and formulations
|
|
US2002115718A1
|
|
Divalproex sodium tablets
|
|
US2002156066A1
|
|
Serotonin reuptake inhibitor formulations
|
|
NZ530584A
|
|
HMG-COA reductase inhibitor extended release formulation
|
|
CA2389973A1
|
|
Method of treating amyloid beta precursor disorders
|
|
GB0210619D0
|
|
HMG-COA reductase inhibitor extended release formulation
|
|
US6544556B1
|
|
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
|
US6099862A
|
|
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
|
US6106862A
|
|
Once daily analgesic tablet
|
